XML 27 R12.htm IDEA: XBRL DOCUMENT v3.6.0.2
Equity Method Investments
3 Months Ended
Nov. 30, 2016
Equity Method Investments [Abstract]  
Equity Method Investments
Note 4. Equity Method Investments
Equity method investments as of November 30, 2016 and August 31, 2016, are as follows (in millions, except percentages):

  
November 30, 2016
  
August 31, 2016
 
  
Carrying
Value
  
Ownership
Percentage
  
Carrying
Value
  
Ownership
Percentage
 
AmerisourceBergen
 
$
4,968
   
26%
 
 
$
4,964
   
24%
 
Others
 
 
1,168
   
12% - 50%
 
  
1,210
   
12% - 50%
 
Total
 
$
6,136
      
$
6,174
     

AmerisourceBergen Investment
As of November 30, 2016 and August 31, 2016, the Company owned 56,854,867 AmerisourceBergen Corporation (“AmerisourceBergen”) common shares, representing approximately 26% and 24% of the outstanding AmerisourceBergen common stock, respectively. The Company accounts for its equity investment in AmerisourceBergen using the equity method of accounting, with the net earnings attributable to the Company’s investment being classified within the operating income of its Pharmaceutical Wholesale segment. Due to the timing and availability of financial information of AmerisourceBergen, the Company accounts for this equity method investment on a financial reporting lag of two months. Equity earnings from AmerisourceBergen is reported as a separate line in the Consolidated Condensed Statements of Earnings. The level 1 fair market value of the Company’s equity investment in AmerisourceBergen common stock at November 30, 2016 is $4.4 billion.

The Company’s investment in AmerisourceBergen carrying value exceeded its proportionate share of the net assets of AmerisourceBergen by $4.4 billion. This premium of $4.4 billion was recognized as part of the carrying value in the Company’s equity investment in AmerisourceBergen. The difference was primarily related to goodwill and the fair value of AmerisourceBergen intangible assets.

Other Investments
The Company’s other equity method investments include its investments in Guangzhou Pharmaceuticals Corporation and Nanjing Pharmaceutical Corporation Limited, the Company’s pharmaceutical wholesale investments in China; and the equity method investment retained through the sale of a majority interest in Option Care Inc. in fiscal 2015. The Company reported $12 million and $11 million of post-tax equity earnings from equity method investments other than AmerisourceBergen for the three months ended November 30, 2016 and November 30, 2015, respectively.